Stocks Roundup: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) & Jabil Inc. (NYSE:JBL)

5

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated discovers, develops and markets new drugs that address critical unmet medical needs of patients in the areas of cancer, pain, skin diseases, men’s and women’s hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand’s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology, primarily related to intracellular receptors.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)’s Financial Overview

Ligand Pharmaceuticals Incorporated (NASDAQ) surged 3.05% yesterday to close its trading session at $117.97. The company has 1 year Price Target of $217.33. Ligand Pharmaceuticals Incorporated has 52-Week high of $278.62 and 52-Week Low of $98.56. The stock touched its 52-Week High on 278.62 and 52-Week Low on 98.56. The stock traded with the volume of 689476 shares yesterday. The firm shows the market capitalization of $2.55 Billion.

Ligand Pharmaceuticals Incorporated (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $1.32/share against the analyst consensus estimate of $1.03/share. The difference between the actual and expected EPS is $0.29 a share with a surprise factor of 28.2%.

The firm is trading with SMA20 of 0.02 Percent, SMA50 of -11.24 Percent and SMA200 of -37.88 percent. Ligand Pharmaceuticals Incorporated has P/S value of 10.53 while its P/B value stands at 3.57. Similarly, the company has Return on Assets of 8.9 percent, Return on Equity of 21.6 percent and Return on Investment of 8.7 Percent. The company shows Gross Margin and Operating Margin of 97.9 percent and 62.8 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 6 analysts offering 12-month price forecasts for Ligand Pharmaceuticals Inc have a median target of 215.00, with a high estimate of 281.00 and a low estimate of 168.00. The median estimate represents a +82.25% increase from the last price of 117.97.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Jabil Inc. (NYSE:JBL)

Jabil Inc. provides electronic manufacturing services and solutions. The Company’s operating segment includes Electronics Manufacturing Services and Diversified Manufacturing Services. EMS segment is focused on leveraging information technology, supply chain design and engineering, technologies centered on core electronics. DMS segment is focused on providing engineering solutions and a focus on material sciences and technologies. It provides electronic design, production and product management services to automotive, capital equipment, consumer lifestyles and wearable technologies, computing and storage, defense and aerospace, digital home, emerging growth, healthcare, industrial and energy, mobility, packaging, point of sale and printing industries. Jabil Inc., formerly known as Jabil Circuit Inc., is based in FL, United States.

Jabil Inc. (NYSE:JBL)’s Financial Outlook

The 10 analysts offering 12-month price forecasts for Jabil Inc have a median target of 29.50, with a high estimate of 40.00 and a low estimate of 23.00. The median estimate represents a +7.16% increase from the last price of 27.53.

Jabil Inc. is estimated to report earnings on 03/21/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.49. The reported EPS for the same quarter last year was $0.57.

According to Zacks Investment Research, Jabil Inc. has a Consensus Recommendation of 2.5. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 1.03% and closed its last trading session at $27.53. The company has the market capitalization of $4.28 Billion. The stock has 52-week high of $31.77 and 52-Week low of $21.49. The firm touched its 52-Week high on 31.77 and 52-Week low on 21.49. The company has volume of 1.36 Million shares. The company has a total of 155.4 Million shares outstanding.

Jabil Inc. (NYSE) in the last quarter reported its actual EPS of $0.9/share where the analyst estimated EPS was $0.88/share. The difference between the actual and Estimated EPS is $0.02. This shows a surprise factor of 2.3 percent.

The company has YTD performance of 11.05 percent. Beta for Jabil Inc. stands at 0.58 while its ATR (average true range) is 0.57. The company has Weekly Volatility of 1.72%% and Monthly Volatility of 1.89%%.

Jabil Inc. has distance from 20-day Simple Moving Average (SMA20) of 6.41%, Distance from 50-Day Simple Moving Average of 11.8 percent and Distance from 200-Day Simple Moving Average of 3.06%.

The Company currently has ROA (Return on Assets) of 1.2 percent, Return on Equity (ROE) of 7 Percent and Return on Investment (ROI) of 8.9% with Gross margin of 7.6 percent and Operating & Profit margin of 2.7% and 0.6% respectively.

SHARE